Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

1.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Nov 14;7:13513. doi: 10.1038/ncomms13513. No abstract available.

2.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.

Shukuya T, Mori K, Amann JM, Bertino EM, Otterson GA, Shields PG, Morita S, Carbone DP.

J Thorac Oncol. 2016 Nov;11(11):1927-1939. doi: 10.1016/j.jtho.2016.07.017.

PMID:
27496650
3.

Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm.

Chu BF, Otterson GA.

Clin Lung Cancer. 2016 Nov;17(6):493-506. doi: 10.1016/j.cllc.2016.05.020. Review.

PMID:
27381269
4.

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F.

J Thorac Oncol. 2016 Sep 30. pii: S1556-0864(16)31119-4. doi: 10.1016/j.jtho.2016.09.131. [Epub ahead of print]

PMID:
27697581
5.

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM.

Oncologist. 2016 Oct;21(10):1163-1164.

6.

A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.

Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, Otterson GA.

Mol Cancer Ther. 2016 Sep;15(9):2244-50. doi: 10.1158/1535-7163.MCT-15-0879.

PMID:
27458141
7.

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2016 Jul;14(7):825-36.

PMID:
27407123
8.

Lung cancer exosomes as drivers of epithelial mesenchymal transition.

Rahman MA, Barger JF, Lovat F, Gao M, Otterson GA, Nana-Sinkam P.

Oncotarget. 2016 Jun 23. doi: 10.18632/oncotarget.10243. [Epub ahead of print]

9.

Rad51C-ATXN7 fusion gene expression in colorectal tumors.

Kalvala A, Gao L, Aguila B, Dotts K, Rahman M, Nana-Sinkam SP, Zhou X, Wang QE, Amann J, Otterson GA, Villalona-Calero MA, Duan W.

Mol Cancer. 2016 Jun 13;15(1):47. doi: 10.1186/s12943-016-0527-1.

10.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Jun 10;7:11815. doi: 10.1038/ncomms11815.

11.

Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.

Halasz LM, Uno H, Hughes M, D'Amico T, Dexter EU, Edge SB, Hayman JA, Niland JC, Otterson GA, Pisters KM, Theriault R, Weeks JC, Punglia RS.

Cancer. 2016 Jul 1;122(13):2091-100. doi: 10.1002/cncr.30009.

PMID:
27088755
12.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2016 Mar;14(3):255-64.

PMID:
26957612
13.

Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.

Villalona-Calero MA, Lam E, Otterson GA, Zhao W, Timmons M, Subramaniam D, Hade EM, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp MV.

Cancer. 2016 Mar 15;122(6):875-83. doi: 10.1002/cncr.29856.

14.

CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.

Ozkan E, West A, Dedelow JA, Chu BF, Zhao W, Yildiz VO, Otterson GA, Shilo K, Ghosh S, King M, White RD, Erdal BS.

AJR Am J Roentgenol. 2015 Nov;205(5):1016-25. doi: 10.2214/AJR.14.14147.

PMID:
26496549
15.

Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations.

Burkart J, Shilo K, Zhao W, Ozkan E, Ajam A, Otterson GA.

Case Rep Pulmonol. 2015;2015:283875. doi: 10.1155/2015/283875.

16.

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, Otterson GA, Mekhail T, Snell M, Kuebler JP, Sharma N, Dowlati A.

Oncologist. 2015 Nov;20(11):1298-303. doi: 10.1634/theoncologist.2015-0136.

17.

Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.

Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA.

Clin Lung Cancer. 2015 Nov;16(6):466-74. doi: 10.1016/j.cllc.2015.05.004.

18.

Non-Small Cell Lung Cancer, Version 6.2015.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M; National comprehensive cancer network..

J Natl Compr Canc Netw. 2015 May;13(5):515-24.

PMID:
25964637
19.

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE.

J Clin Oncol. 2015 May 20;33(15):1660-5. doi: 10.1200/JCO.2014.57.3105.

20.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9.

PMID:
25704439
Items per page

Supplemental Content

Loading ...
Support Center